Understanding pRb: Toward the necessary development of targeted treatments for retinoblastoma

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 425-434

  Sachdeva, Uma M ^a   O'Brien, Joan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; NUTLIN 3; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; S PHASE KINASE ASSOCIATED PROTEIN 2; TOPOTECAN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VINCRISTINE;

ARTERY OCCLUSION; BLINDNESS; BRACHYTHERAPY; BRANCH RETINAL ARTERY OCCLUSION; CANCER CLASSIFICATION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL FUNCTION; CELLULITIS; CHOROID DISEASE; CHOROID GYRATE ATROPHY; CHROMOSOME ABERRATION; CRYOTHERAPY; DRUG DELIVERY SYSTEM; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG MEGADOSE; EYE MOVEMENT; EYELID EDEMA; GANGRENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPONATREMIA; LEUKEMIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; MYOSITIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OPHTHALMIC ARTERY OCCLUSION; OPTIC NERVE ATROPHY; ORBIT DISEASE; OTOTOXICITY; PRIORITY JOURNAL; PSEUDO PRESEPTAL CELLULITIS; QUALITY OF LIFE; RADIATION SICKNESS; RETINA BLOOD VESSEL OCCLUSION; RETINOBLASTOMA; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VITREOUS HEMORRHAGE;

ANIMALS; CELL CYCLE; DISEASE MODELS, ANIMAL; GENE THERAPY; GENES, RETINOBLASTOMA; HUMANS; MUTATION; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 84856535848     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57114     Document Type: Review

References (128)

1. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA:1975-2004. Br J Ophthalmol. 2009;93(1):24-27.
2. Canturk S, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94(11):1432-1436.
3. Chantada GL, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer. 2011;56(3):341-348.
4. Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18(1):55-63. (Pubitemid 40348810)
5. Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1994;23(3):151-159. (Pubitemid 24238760)
6. Mulvihill A, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120-1124. (Pubitemid 36962165)
7. Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudopreseptal cellulitis following sub-Tenon's carboplatin injection for intraocular retinoblastoma. J Aapos. 2007;11(4):404-405. (Pubitemid 47198495)
8. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947- 1950.
9. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142(2):310-315.
10. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol. 2000;109(1):13-23. (Pubitemid 30340574)
11. Gombos DS, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114(7):1378-1383. (Pubitemid 47008929)
12. Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148(2):192-198.
13. Scott IU, et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol. 1999;117(6):766-770. (Pubitemid 29265037)
14. Wong FL, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267. (Pubitemid 27435614)
15. Bunin GR, Meadows AT, Emanuel BS, Buckley JD, Woods WG, Hammond GD. Pre- and post-conception factors associated with sporadic heritable and nonheritable retinoblastoma. Cancer Res. 1989;49(20):5730-5735. (Pubitemid 19256460)
16. Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001;119(11):1699-1704. (Pubitemid 33035714)
17. Moll AC, et al. Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994. Int J Cancer. 1996;67(4):515-519. (Pubitemid 26274108)
18. Eng C, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-1128. (Pubitemid 23212278)
19. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96(5):357-363. (Pubitemid 38401013)
20. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671-682.
21. De Falco G, Comes F, Simone C. pRb: master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specific transcription. Oncogene. 2006;25(38):5244-5249. (Pubitemid 44299083)
22. Ferguson KL, et al. A cell-autonomous requirement for the cell cycle regulatory protein, Rb, in neuronal migration. Embo J. 2005;24(24):4381-4391. (Pubitemid 41828912)
23. Ferguson KL, Slack RS. The Rb pathway in neurogenesis. Neuroreport. 2001;12(9):A55-62. (Pubitemid 32553684)
24. Harbour JW. Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening. Ophthalmology. 1998;105(8):1442-1447. (Pubitemid 28509762)
25. Xiao B, et al. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci U S A. 2003;100(5):2363-2368. (Pubitemid 36297504)
26. Ji P, et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell. 2004;16(1):47-58. (Pubitemid 39330151)
27. Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA. Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol. 2006;4:14.
28. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene. 1998;17(25):3365-3383. (Pubitemid 29043989)
29. Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796-2809. (Pubitemid 40638091)
30. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785-797.
31. Lacy ER, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol. 2004;11(4):358-364. (Pubitemid 38436801)
32. Chu I, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128(2):281-294. (Pubitemid 46123510)
33. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253-267. (Pubitemid 351430863)
34. Suzuki-Takahashi I, et al. The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase. Oncogene. 1995;10(9):1691-1698.
35. Ianari A, et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell. 2009;15(3):184-194.
36. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene. 1996;12(9):1909-1919. (Pubitemid 26154663)
37. Gottlieb E, Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. Embo J. 1998;17(13):3587-3596. (Pubitemid 28327377)
38. Abouzeid H, Munier FL, Thonney F, Schorderet DF. Ten novel RB1 gene mutations in patients with retinoblastoma. Mol Vis. 2007;13:1740-1745. (Pubitemid 47496496)
39. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391(6667):597-601. (Pubitemid 28157603)
40. Magnaghi-Jaulin L, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998;391(6667):601-605. (Pubitemid 28157604)
41. Binne UK, et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol. 2007;9(2):225-232. (Pubitemid 46420866)
42. Liu X, Marmorstein R. Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev. 2007;21(21):2711-2716. (Pubitemid 350070718)
43. Liu X, Marmorstein R. When viral oncoprotein meets tumor suppressor: a structural view. Genes Dev. 2006;20(17):2332-2337. (Pubitemid 44320381)
44. Yaginuma Y, et al. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res. 1997;233(2):233-239. (Pubitemid 27252004)
45. Henley SA, Francis SM, Demone J, Ainsworth P, Dick FA. A cancer derived mutation in the retinoblastoma gene with a distinct defect for LXCXE dependent interactions. Cancer Cell Int. 2010;10:8.
46. Isaac CE, et al. The retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol. 2006;26(9):3659-3671.
47. Bourgo RJ, et al. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell. 2011;43(4):663-672.
48. Knudsen KE, et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol. 2000;20(20):7751-7763.
49. Bosco EE, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 2007;117(1):218-228. (Pubitemid 46048468)
50. Derenzini M, et al. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res. 2008;14(7):2199-2209. (Pubitemid 351551133)
51. DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol. 2000;10(4):255-269.
52. Retinoblastoma Genetics. Retinoblastoma Genetics web site. http://rb1-lsdb.d-lohmann.de. Updated January 31, 2006. Accessed December 15, 2011.
53. Dick FA. Structure-function analysis of the retinoblastoma tumor suppressor protein - is the whole a sum of its parts? Cell Div. 2007;2:26.
54. Sellers WR, et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 1998;12(1):95-106. (Pubitemid 28083661)
55. Sidle A, et al. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol. 1996;31(3):237-271. (Pubitemid 26242314)
56. Chen PL, Scully P, Shew JY, Wang JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989;58(6):1193-1198. (Pubitemid 19238195)
57. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323-330.
58. Tamrakar S, Rubin E, Ludlow JW. Role of pRB dephosphorylation in cell cycle regulation. Front Biosci. 2000;5:D121-D137.
59. DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992;89(5):1795-1798.
60. Furukawa Y, et al. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A. 1990;87(7):2770-2774.
61. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12(15):2245-2262. (Pubitemid 28371346)
62. Yung Y, Walker JL, Roberts JM, Assoian RK. A Skp2 autoinduction loop and restriction point control. J Cell Biol. 2007;178(5):741-747. (Pubitemid 47347359)
63. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996;271(14):8313-8320. (Pubitemid 26108665)
64. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-1512. (Pubitemid 29297917)
65. Hernando E, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430(7001):797-802. (Pubitemid 39071352)
66. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 2010;24(13):1364-1376.
67. Sotillo R, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 2007;11(1):9-23. (Pubitemid 46054519)
68. Gonzalo S, et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol. 2005;7(4):420-428. (Pubitemid 40533133)
69. Longworth MS, Herr A, Ji JY, Dyson NJ. RBF1 promotes chromatin condensation through a conserved interaction with the Condensin II protein dCAP-D3. Genes Dev. 2008;22(8):1011-1024. (Pubitemid 351544240)
70. Squire J, Gallie BL, Phillips RA. A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Hum Genet. 1985;70(4):291-301. (Pubitemid 16241979)
71. Windle JJ, et al. Retinoblastoma in transgenic mice. Nature. 1990;343(6259):665-669.
72. al-Ubaidi MR, et al. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J Cell Biol. 1992;119(6):1681-1687.
73. Marcus DM, et al. Trilateral tumors in four different lines of transgenic mice expressing SV40 T-antigen. Invest Ophthalmol Vis Sci. 1996;37(2):392-396. (Pubitemid 26057065)
74. al-Ubaidi MR, Hollyfield JG, Overbeek PA, Baehr W. Photoreceptor degeneration induced by the expression of simian virus 40 large tumor antigen in the retina of transgenic mice. Proc Natl Acad Sci U S A. 1992;89(4):1194-1198.
75. Mahon KA, Chepelinsky AB, Khillan JS, Overbeek PA, Piatigorsky J, Westphal H. Oncogenesis of the lens in transgenic mice. Science. 1987;235(4796):1622-1628. (Pubitemid 17050144)
76. Conway RM, Wheeler SM, Murray TG, Jockovich ME, O'Brien JM. Retinoblastoma: animal models. Ophthalmol Clin North Am. 2005;18(1):25-39. (Pubitemid 40348808)
77. Howes KA, Ransom N, Papermaster DS, Lasudry JG, Albert DM, Windle JJ. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 1994;8(11):1300-1310. (Pubitemid 24181321)
78. Mills MD, Windle JJ, Albert DM. Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Surv Ophthalmol. 1999;43(6):508-518. (Pubitemid 29330765)
79. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature. 1992;359(6393):295-300.
80. Lee EY, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature. 1992;359(6393):288-294.
81. Wu L, et al. Extra-embryonic function of Rb is essential for embryonic development and viability. Nature. 2003;421(6926):942-947. (Pubitemid 36288025)
82. Robanus-Maandag E, et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 1998;12(11):1599-1609. (Pubitemid 28299512)
83. Laurie NA, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444(7115):61-66. (Pubitemid 44684754)
84. Schlamp CL, Poulsen GL, Nork TM, Nickells RW. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J Natl Cancer Inst. 1997;89(20):1530-1536. (Pubitemid 27441178)
85. Donehower LA, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
86. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993;5(3):225-229. (Pubitemid 23330383)
87. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet. 1994;8(1):66-69.
88. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995;10(2):175-180.
89. Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, Nishina PM. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci. 1999;40(8):1874-1878. (Pubitemid 29297170)
90. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene. 2006;25(5):746-755.
91. Frame FM, Rogoff HA, Pickering MT, Cress WD, Kowalik TF. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene. 2006;25(23):3258-3266. (Pubitemid 43846310)
92. Garner E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle. 2008;7(3):277-282. (Pubitemid 351366487)
93. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res. 2006;66(21):10258-10263. (Pubitemid 44799741)
94. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10(1):94-99. (Pubitemid 30113711)
95. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46(7):617-634. (Pubitemid 46802329)
96. Gratias S, et al. Genomic gains on chromosome 1q in retinoblastoma: consequences on gene expression and association with clinical manifestation. Int J Cancer. 2005;116(4):555-563. (Pubitemid 41099191)
97. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24(30):4741-4753. (Pubitemid 41076292)
98. Dimaras H, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet. 2008;17(10):1363-1372. (Pubitemid 351627333)
99. Bowles E, et al Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer. 2007;46(2):118-129. (Pubitemid 44913377)
100. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 2006;26(20):7506-7519. (Pubitemid 44547701)
101. Khodadoust MS, et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 2009;69(16):6405-6413.
102. Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res. 2010;16(6):1824-1833.
103. Wise-Draper TM, et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol. 2009;174(1):71-81.
104. Kappes F, et al. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol. 2008;28(10):3245-3257. (Pubitemid 351657089)
105. Wise-Draper TM, et al. The human DEK protooncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol. 2005;79(22):14309-14317. (Pubitemid 41552728)
106. Brennan RC, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011;71(12):4205-4213.
107. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005;102(44):16090-16095. (Pubitemid 41552872)
108. Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008;14(10):3113-3123.
109. Xu XL, et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell. 2009;137(6):1018-1031.
110. Guo Y, Pajovic S, Gallie BL. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. Biochem Biophys Res Commun. 2008;375(1):1-5.
111. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature. 2009;462(7275):925-929.
112. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell. 2004;5(6):539-551. (Pubitemid 38748916)
113. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69-73. (Pubitemid 38619319)
114. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78(8):858-868. (Pubitemid 17124771)
115. Graeber CP, et al. Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma. Open Ophthalmol J. 2011;5:1-5.
116. Shields CL, et al. Intra-arterial chemotherapy for retinoblastoma: report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399-1406.
117. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2011;114(6):1603-1608.
118. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737.
119. Shields CL, et al. Intra-arterial chemotherapy for retinoblastoma: report no. 2, treatment complications. Arch Ophthalmol. 2011;129(11):1407-1415.
120. Vajzovic LM, et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol. 2011;5:171-176.
121. Antczak C, et al. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. Invest Ophthalmol Vis Sci. 2009;50(7):3065-3073.
122. Patel M, et al. Intra-arterial and oral digoxin therapy for retinoblastoma. Ophthalmic Genet. 2011;32(3):147-150.
123. Eser U, Falleur-Fettig M, Johnson A, Skotheim JM. Commitment to a cellular transition precedes genome-wide transcriptional change. Mol Cell. 2011;43(4):515-527.
124. Saenz Robles MT, Case A, Chong JL, Leone G, Pipas JM. The retinoblastoma tumor suppressor regulates a xenobiotic detoxification pathway. PLoS ONE. 2010;6(10):e26019.
125. Sdek P, et al. Rb and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes. J Cell Biol. 2011;194(3):407-423.
126. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98(6):859-869. (Pubitemid 29446902)
127. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997; 272(19):12738-12746. (Pubitemid 27203373)
128. Tomicic MT, Christmann M, Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther. 2010;332(1):316-325.